Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
Jazyk angličtina Země Francie Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
29501768
DOI
10.1016/j.biopha.2018.02.108
PII: S0753-3322(17)34026-X
Knihovny.cz E-zdroje
- Klíčová slova
- Antimetabolites, Antimitotic agents, Chemotherapy, DNA alkylating agents, Efficacy, Hormonal/endocrine therapy, Immunologic therapy, Ion modulators, Metastatic breast cancer, Resistance, Toxicity,
- MeSH
- chemorezistence účinky léků MeSH
- lidé MeSH
- nádory prsu farmakoterapie MeSH
- protinádorové látky terapeutické užití MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- protinádorové látky MeSH
Breast cancer is the second greatest cause of death among women worldwide; it comprises a group of heterogeneous diseases that evolves due to uncontrolled cellular growth and differentiation and the loss of normal programmed cell death. There are different molecular sub-types of breast cancer; therefore, various options are selected for treatment of different forms of metastatic breast cancer. However, the use of chemotherapeutic drugs is usually accompanied by deleterious side effects and the development of drug resistance when applied for a longer period. This review offers a classification of these chemotherapeutic agents according to their modes of action and therefore improves the understanding of molecular targets that are affected during treatment. Overall, it will allow the clinician to identify more specific targets to increase the effectiveness of a drug and to reduce general toxicity, resistance and other side effects.
Citace poskytuje Crossref.org
New uses of halofuginone to treat cancer
